Lalit Verma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lalit Verma has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Avnindra Gupta
Department of Vitreo-retina Services, Centre for Sight, New Delhi, India
7 shared publicationsHem K Tewari
6 shared publicationsArindam Chakravarti
Centre for Sight, New Delhi, India
4 shared publicationsDinesh Talwar
Department of Vitreo-retina Services, Centre for Sight, New Delhi, India
3 shared publicationsPradeep Venkatesh
3 shared publicationsSanjeev Nainiwal
3 shared publications
Latest Publications
- Open Access
- 27 May 2026
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 74 (6) , 893-900
Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy)
Purpose: To assess the long-term safety and efficacy of intravitreal brolucizumab (Pagenax®) in eyes with chronic central serous chorioretinopathy (CSC) complicated by neovascularization (pachychoroid neovasculopathy) refractory to prior therapies. Methods: In this single-center retrospective case series (January 2021–July 2025), 30 eyes of 25 patients with recalcitrant and refractory cases of chronic CSC with secondary neovascularization were treated off-label with pro-re-nata intravitreal brolucizumab. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and pigment epithelial detachment (PED) height were measured at baseline and 6 months, with extended outcomes in nine eyes assessed at 1 and 2 years. Adverse events were recorded at each visit. Results: At 6 months, the mean CST decreased significantly from 328 ± 222 µm to 172 ± 79 µm ( P < 0.001), and the PED height declined from 262 ± 192 µm to 155 ± 123 µm ( P = 0.027). BCVA improved or remained stable in 90% of eyes, with no significant change in mean logMAR (0.38 to 0.33, P = 0.314). In the extended cohort, CST reductions persisted at 1 year (412 ± 241 µm to 271 ± 239 µm, P = 0.009) and 2 years (412 ± 241 µm to 164 ± 42 µm, P = 0.004), while BCVA stayed stable. A weak correlation suggested more injections might be linked to slightly poorer BCVA, possibly due to resistant cases requiring more treatment. No adverse events were noted. Conclusion: Intravitreal brolucizumab administered PRN effectively resolves persistent fluid and reduces PED in chronic CSC with PNV refractory to prior treatments, while maintaining stable visual acuity and demonstrating a favorable safety profile through 2 years of follow-up.
- 27 May 2026
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 74 (6) , 893-900
Open AccessLong-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy)
Purpose: To assess the long-term safety and efficacy of intravitreal brolucizumab (Pagenax®) in eyes with chronic central serous chorioretinopathy (CSC) complicated by neovascularization (pachychoroid neovasculopathy) refractory to prior therapies. Methods: In this single-center retrospective case series (January 2021–July 2025), 30 eyes of 25 patients with recalcitrant and refractory cases of chronic CSC with secondary neovascularization were treated off-label with pro-re-nata intravitreal brolucizumab. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and pigment epithelial detachment (PED) height were measured at baseline and 6 months, with extended outcomes in nine eyes assessed at 1 and 2 years. Adverse events were recorded at each visit. Results: At 6 months, the mean CST decreased significantly from 328 ± 222 µm to 172 ± 79 µm ( P < 0.001), and the PED height declined from 262 ± 192 µm to 155 ± 123 µm ( P = 0.027). BCVA improved or remained stable in 90% of eyes, with no significant change in mean logMAR (0.38 to 0.33, P = 0.314). In the extended cohort, CST reductions persisted at 1 year (412 ± 241 µm to 271 ± 239 µm, P = 0.009) and 2 years (412 ± 241 µm to 164 ± 42 µm, P = 0.004), while BCVA stayed stable. A weak correlation suggested more injections might be linked to slightly poorer BCVA, possibly due to resistant cases requiring more treatment. No adverse events were noted. Conclusion: Intravitreal brolucizumab administered PRN effectively resolves persistent fluid and reduces PED in chronic CSC with PNV refractory to prior treatments, while maintaining stable visual acuity and demonstrating a favorable safety profile through 2 years of follow-up.
- Open Access
- 29 April 2026
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 74 (5) , 635-638
Peep into anti-vascular endothelial growth factor
Anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the management of retinal vascular diseases over the past two decades. Beginning with the foundational identification of VEGF as the principal driver of ocular neovascularization, the field has evolved from early agents such as pegaptanib and bevacizumab to more potent molecules including ranibizumab, aflibercept, brolucizumab, and faricimab. In India, the landscape is shaped by unique economic and epidemiological factors, including a high burden of diabetic retinopathy and age-related macular degeneration, limited healthcare reimbursement, and the significant role of biosimilar ranibizumab products in expanding access. This article provides a comprehensive overview of the historical development, pharmacology, regulatory milestones, safety considerations, and current clinical use of anti-VEGF agents in the Indian context, with emphasis on strategies to deliver equitable, high quality retinal care across a diverse population.
- 29 April 2026
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 74 (5) , 635-638
Open AccessPeep into anti-vascular endothelial growth factor
Anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed the management of retinal vascular diseases over the past two decades. Beginning with the foundational identification of VEGF as the principal driver of ocular neovascularization, the field has evolved from early agents such as pegaptanib and bevacizumab to more potent molecules including ranibizumab, aflibercept, brolucizumab, and faricimab. In India, the landscape is shaped by unique economic and epidemiological factors, including a high burden of diabetic retinopathy and age-related macular degeneration, limited healthcare reimbursement, and the significant role of biosimilar ranibizumab products in expanding access. This article provides a comprehensive overview of the historical development, pharmacology, regulatory milestones, safety considerations, and current clinical use of anti-VEGF agents in the Indian context, with emphasis on strategies to deliver equitable, high quality retinal care across a diverse population.
- Open Access
- 15 December 2023
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 72 (2) , 287-288
Use of 30 gauge needle to prevent hypotony during silicone oil removal
Silicone oil (SO) is used as an intraocular tamponade after complex vitreoretinal surgeries because of its properties such as transparency, inertness, high surface tension, and interfacial tension with water. The only disadvantage of SO tamponade is the need for a second surgery for its removal. However, there is a risk of ocular hypotony soon after the removal of the infusion cannula, especially in retinal vascular conditions, such as diabetic retinopathy. We hereby present a silicone oil removal (SOR) technique using a 30 G needle that prevents intraocular hypotony during SOR.
- 15 December 2023
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 72 (2) , 287-288
Open AccessUse of 30 gauge needle to prevent hypotony during silicone oil removal
Silicone oil (SO) is used as an intraocular tamponade after complex vitreoretinal surgeries because of its properties such as transparency, inertness, high surface tension, and interfacial tension with water. The only disadvantage of SO tamponade is the need for a second surgery for its removal. However, there is a risk of ocular hypotony soon after the removal of the infusion cannula, especially in retinal vascular conditions, such as diabetic retinopathy. We hereby present a silicone oil removal (SOR) technique using a 30 G needle that prevents intraocular hypotony during SOR.
- Open Access
- 30 November 2022
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 70 (12) , 4457-4458
Response to comments on: All India Ophthalmological Society (AIOS) task force guidelines to prevent intraocular infections
- 30 November 2022
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 70 (12) , 4457-4458
Open AccessResponse to comments on: All India Ophthalmological Society (AIOS) task force guidelines to prevent intraocular infections
- Open Access
- 27 January 2022
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 70 (2) , 362-368
All India Ophthalmological Society (AIOS) Task Force guidelines to prevent intraocular infections and cluster outbreaks after cataract surgery
Infectious endophthalmitis is a serious and vision-threatening complication of commonly performed intraocular surgeries such as cataract surgery. The occurrence of endophthalmitis can result in severe damage to the uveal and other ocular tissues even among patients undergoing an uncomplicated surgical procedure. If the infections result from common factors such as surgical supplies, operative or operation theater-related risks, there can be a cluster outbreak of toxic anterior segment syndrome (TASS) or infectious endophthalmitis, leading to several patients having an undesirable outcome. Since prevention of intraocular infections is of paramount importance to ophthalmic surgeons, the All India Ophthalmological Society (AIOS) has taken the lead in the formation of a National Task Force to help ophthalmic surgeons apply certain universal precautions in their clinical practice. The Task Force has prepared a handy checklist and evidence-based guidelines to minimize the risk of infectious endophthalmitis following cataract surgery.
- 27 January 2022
- Published by Wolters Kluwer Health in Indian Journal Of Ophthalmology
- Vol. 70 (2) , 362-368
Open AccessAll India Ophthalmological Society (AIOS) Task Force guidelines to prevent intraocular infections and cluster outbreaks after cataract surgery
Infectious endophthalmitis is a serious and vision-threatening complication of commonly performed intraocular surgeries such as cataract surgery. The occurrence of endophthalmitis can result in severe damage to the uveal and other ocular tissues even among patients undergoing an uncomplicated surgical procedure. If the infections result from common factors such as surgical supplies, operative or operation theater-related risks, there can be a cluster outbreak of toxic anterior segment syndrome (TASS) or infectious endophthalmitis, leading to several patients having an undesirable outcome. Since prevention of intraocular infections is of paramount importance to ophthalmic surgeons, the All India Ophthalmological Society (AIOS) has taken the lead in the formation of a National Task Force to help ophthalmic surgeons apply certain universal precautions in their clinical practice. The Task Force has prepared a handy checklist and evidence-based guidelines to minimize the risk of infectious endophthalmitis following cataract surgery.
- Open Access
- 1 February 2021
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 69 (2) , 410-416
Essentials of setting up a wet lab for ophthalmic surgical training in COVID-19 pandemic
Wet labs are an extremely important training tool, especially in times of a global COVID-19 pandemic, where surgical training can be minimal. They help the trainee learn and practice in a risk-free environment, without an imminent of a complication or failure, also allowing them the chance to execute the steps of a surgery repeatedly. We summarize all the key ingredients required from setting up a wet lab to improve the surgical skill of the trainees. The review also discusses various eyeball fixating devices, preparation of the eye for various types of ocular surgeries, and the role of simulation-based training in today's scenario.
- 1 February 2021
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 69 (2) , 410-416
Open AccessEssentials of setting up a wet lab for ophthalmic surgical training in COVID-19 pandemic
Wet labs are an extremely important training tool, especially in times of a global COVID-19 pandemic, where surgical training can be minimal. They help the trainee learn and practice in a risk-free environment, without an imminent of a complication or failure, also allowing them the chance to execute the steps of a surgery repeatedly. We summarize all the key ingredients required from setting up a wet lab to improve the surgical skill of the trainees. The review also discusses various eyeball fixating devices, preparation of the eye for various types of ocular surgeries, and the role of simulation-based training in today's scenario.
- Open Access
- 1 February 2021
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 69 (2) , 347-351
Clinical efficacy and safety of Razumab® (CESAR) study
Purpose: The aim of this study was to evaluate the efficacy and safety of Razumab (the biosimilar Ranibizumab by Intas Pharmaceuticals Ltd.) for the treatment of chorioretinal vascular diseases such as diabetic macular edema (DME), choroidal neovascular membrane (CNVM), and macular edema secondary to retinal vein occlusion (RVO). Methods: We conducted a single-center, retrospective study, including patients with DME, CNVM, and RVO, who had received treatment with Razumab® between October 2018 and September 2019. Primary outcome measures were the changes in corrected distance visual acuity (CDVA) and central foveal thickness (CFT) from baseline to 1 month and 3 months. Secondary outcome measures included intraocular pressure (IOP) at day 1, any signs of ocular inflammation or systemic adverse events during the follow-up. Results: One hundred and fifty-three eyes of 141 patients were analyzed. The indications included DME in 70 (45.8%) eyes, CNVM in 70 (45.8%) eyes, and RVO in 13 (8.4%) eyes. Mean CDVA improved from baseline (0.62 ± 0.44) to month 1 (0.45 ± 0.42) and maintained till 3 months (0.42 ± 0.44; P < 0.001). Mean CFT showed significant reduction from baseline (405.68 ± 192.422 μm) to month 1 (286.08 ± 118.36 μm) and month 3 (271 ± 104.24 μm; P < 0.001). None of the eyes recorded IOP >20 mmHg on day 1. No evidence of ocular toxicity or systemic adverse event was noted. Conclusion: Razumab® showed a rapid improvement in CDVA and CFT in most of the eyes with efficacy observed as early as 1 month and maintained till 3 months. The biosimilar Ranibizumab can be a safe and effective low-cost drug for treating macular diseases.
- 1 February 2021
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 69 (2) , 347-351
Open AccessClinical efficacy and safety of Razumab® (CESAR) study
Purpose: The aim of this study was to evaluate the efficacy and safety of Razumab (the biosimilar Ranibizumab by Intas Pharmaceuticals Ltd.) for the treatment of chorioretinal vascular diseases such as diabetic macular edema (DME), choroidal neovascular membrane (CNVM), and macular edema secondary to retinal vein occlusion (RVO). Methods: We conducted a single-center, retrospective study, including patients with DME, CNVM, and RVO, who had received treatment with Razumab® between October 2018 and September 2019. Primary outcome measures were the changes in corrected distance visual acuity (CDVA) and central foveal thickness (CFT) from baseline to 1 month and 3 months. Secondary outcome measures included intraocular pressure (IOP) at day 1, any signs of ocular inflammation or systemic adverse events during the follow-up. Results: One hundred and fifty-three eyes of 141 patients were analyzed. The indications included DME in 70 (45.8%) eyes, CNVM in 70 (45.8%) eyes, and RVO in 13 (8.4%) eyes. Mean CDVA improved from baseline (0.62 ± 0.44) to month 1 (0.45 ± 0.42) and maintained till 3 months (0.42 ± 0.44; P < 0.001). Mean CFT showed significant reduction from baseline (405.68 ± 192.422 μm) to month 1 (286.08 ± 118.36 μm) and month 3 (271 ± 104.24 μm; P < 0.001). None of the eyes recorded IOP >20 mmHg on day 1. No evidence of ocular toxicity or systemic adverse event was noted. Conclusion: Razumab® showed a rapid improvement in CDVA and CFT in most of the eyes with efficacy observed as early as 1 month and maintained till 3 months. The biosimilar Ranibizumab can be a safe and effective low-cost drug for treating macular diseases.
- Open Access
- 1 December 2020
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 14, 4279-4285
Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series
Purpose: To report a case series of four ocular toxoplasmosis patients who received intravitreal clindamycin as first-line treatment. Materials and Methods: Retrospective interventional case series. Results: Four (two females and two males) patients were diagnosed with active primary toxoplasmic retinochoroiditis based on their clinical presentation. All patients received intravitreal clindamycin 1mg/0.1mL as first-line therapy (two injections with 1-week interval). Oral corticosteroid 1mg/kg/day was also given in a tapering fashion over 4– 6 weeks. A remarkable response was seen in all cases with improved visual acuity, sharpening of the lesion borders, and resolution of inflammation within 4– 6 weeks. No recurrence or reactivation was noted until 2 years follow-up. Conclusion: Intravitreal clindamycin, combined with oral corticosteroids, can be considered an effective and safe first-line therapy for active toxoplasmic retinochoroiditis. It provides the patient a more convenience, safer systemic side effect profile, increased availability, and fewer follow-up visits and hematologic investigations.
- 1 December 2020
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 14, 4279-4285
Open AccessIntravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series
Purpose: To report a case series of four ocular toxoplasmosis patients who received intravitreal clindamycin as first-line treatment. Materials and Methods: Retrospective interventional case series. Results: Four (two females and two males) patients were diagnosed with active primary toxoplasmic retinochoroiditis based on their clinical presentation. All patients received intravitreal clindamycin 1mg/0.1mL as first-line therapy (two injections with 1-week interval). Oral corticosteroid 1mg/kg/day was also given in a tapering fashion over 4– 6 weeks. A remarkable response was seen in all cases with improved visual acuity, sharpening of the lesion borders, and resolution of inflammation within 4– 6 weeks. No recurrence or reactivation was noted until 2 years follow-up. Conclusion: Intravitreal clindamycin, combined with oral corticosteroids, can be considered an effective and safe first-line therapy for active toxoplasmic retinochoroiditis. It provides the patient a more convenience, safer systemic side effect profile, increased availability, and fewer follow-up visits and hematologic investigations.
- Open Access
- 1 January 2017
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 65 (12) , 1396-1402
Prevention and management of postoperative endophthalmitis: A case-based approach
Endophthalmitis following intraocular surgery is a disastrous complication and can lead to poor visual outcomes and loss of globe integrity. It should be differentiated from toxic anterior segment syndrome (TASS) where management differs drastically. This article presents basic knowledge about postoperative endophthalmitis and describes nine different real–world scenarios ranging from TASS to milder forms of endophthalmitis responding to intravitreal antibiotics alone and more complicated forms associated with corneal involvement, fungal endophthalmitis and cases requiring intraocular lens removal, radical vitrectomy with hyaloid peeling, base dissection, and silicone oil. A case-based approach is followed where practical considerations have been adopted with each case such that it facilitates the readers' ability to apply theoretical knowledge to real-life clinical situations.
- 1 January 2017
- Published by Medknow in Indian Journal Of Ophthalmology
- Vol. 65 (12) , 1396-1402
Open AccessPrevention and management of postoperative endophthalmitis: A case-based approach
Endophthalmitis following intraocular surgery is a disastrous complication and can lead to poor visual outcomes and loss of globe integrity. It should be differentiated from toxic anterior segment syndrome (TASS) where management differs drastically. This article presents basic knowledge about postoperative endophthalmitis and describes nine different real–world scenarios ranging from TASS to milder forms of endophthalmitis responding to intravitreal antibiotics alone and more complicated forms associated with corneal involvement, fungal endophthalmitis and cases requiring intraocular lens removal, radical vitrectomy with hyaloid peeling, base dissection, and silicone oil. A case-based approach is followed where practical considerations have been adopted with each case such that it facilitates the readers' ability to apply theoretical knowledge to real-life clinical situations.
- 1 September 2014
- Published by Wolters Kluwer Health in Retina
- Vol. 34 (9) , 1911-1913
Diagnostic and Therapeutic Challenges
- 1 September 2014
- Published by Wolters Kluwer Health in Retina
- Vol. 34 (9) , 1911-1913
Diagnostic and Therapeutic Challenges